{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:22:33Z","timestamp":1769602953630,"version":"3.49.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,14]],"date-time":"2016-09-14T00:00:00Z","timestamp":1473811200000},"content-version":"vor","delay-in-days":349,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","derm.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.det.2015.05.004","type":"journal-article","created":{"date-parts":[[2015,8,10]],"date-time":"2015-08-10T15:15:46Z","timestamp":1439219746000},"page":"683-696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Skin-Directed Therapies in Cutaneous T-Cell Lymphoma"],"prefix":"10.1016","volume":"33","author":[{"given":"Cuong V.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly A.","family":"Bohjanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2015.05.004_bib1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib2","unstructured":"National Comprehensive Cancer Network. Non-Hodgkin\u2019s lymphoma (Version 4.2014). Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf. Accessed October 18, 2014."},{"key":"10.1016\/j.det.2015.05.004_bib3","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"Olsen","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2015.05.004_bib4","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0190-9622(99)70491-3","article-title":"Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients","volume":"40","author":"Zackheim","year":"1999","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/archderm.1996.03890350051009","article-title":"Clinical stage IA (limited patch and plaque) mycosis fungoides","volume":"132","author":"Kim","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib6","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1001\/archderm.135.1.26","article-title":"Clinical characteristics and long-term outcome of patients with generalized patch and\/or plaque (T2) mycosis fungoides","volume":"135","author":"Kim","year":"1999","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib7","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJM198912283212603","article-title":"A\u00a0randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides","volume":"321","author":"Kaye","year":"1989","journal-title":"N\u00a0Eng J Med"},{"key":"10.1016\/j.det.2015.05.004_bib8","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1600-0625.2008.00786.x","article-title":"The skin: an indispensable barrier","volume":"17","author":"Proksch","year":"2008","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1034\/j.1600-0846.2001.070401.x","article-title":"Instrumental and dermatologist evaluation of the effect of glycerine and urea on dry skin in atopic dermatitis","volume":"7","author":"Lod\u00e9n","year":"2001","journal-title":"Skin Res Technol"},{"key":"10.1016\/j.det.2015.05.004_bib10","first-page":"51","article-title":"Prevention of stratum corneum lipid phase transitions in\u00a0vitro by glycerol \u2013 an alternative mechanism for skin moisturization","volume":"41","author":"Froebe","year":"1990","journal-title":"J\u00a0Soc Cosmet Chem"},{"key":"10.1016\/j.det.2015.05.004_bib11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/BF00373429","article-title":"The effect of glycerol and humidity on desmosome degradation in stratum corneum","volume":"287","author":"Rawlings","year":"1995","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.det.2015.05.004_bib12","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1067\/mjd.2001.113478","article-title":"A\u00a0phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma","volume":"44","author":"Duvic","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib13","series-title":"Comprehensive dermatologic drug therapy","first-page":"487","article-title":"Topical corticosteroids","author":"Wolverton","year":"2013"},{"key":"10.1016\/j.det.2015.05.004_bib14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000236781","article-title":"Glucocorticoid-induced apoptosis of lymphoid cells","volume":"105","author":"Schwartzman","year":"1994","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.det.2015.05.004_bib15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1001\/archderm.1963.01590190026002","article-title":"Existence of reservoir in the stratum corneum: Experimental proof","volume":"88","author":"Vickers","year":"1963","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/1097-0142(196602)19:2<237::AID-CNCR2820190216>3.0.CO;2-P","article-title":"Therapy of mycosis fungoides with topically applied fluocinolone acetonide under occlusive dressing","volume":"19","author":"Farber","year":"1966","journal-title":"Cancer"},{"key":"10.1016\/j.det.2015.05.004_bib17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archderm.1968.01610080069013","article-title":"Treatment of mycosis fungoides with various strengths of fluocinolone acetonide cream","volume":"97","author":"Farber","year":"1968","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib18","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archderm.134.8.949","article-title":"Topical corticosteroids for mycosis fungoides. Experience in 79 patients","volume":"134","author":"Zackheim","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1396-0296.2003.01639.x","article-title":"Treatment of patch-stage mycosis fungoides with topical corticosteroids","volume":"16","author":"Zackheim","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.det.2015.05.004_bib20","article-title":"Diagnosis and treatment of S\u00e9zary syndrome","volume":"2","author":"Harrison","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib21","first-page":"1531","article-title":"Guidelines for using superpotent topical steroids","volume":"41","author":"Prawer","year":"1990","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.det.2015.05.004_bib22","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S0190-9622(87)70105-4","article-title":"Superpotent topical steroid treatment of psoriasis vulgaris: clinical efficacy and adrenal function","volume":"16","author":"Katz","year":"1987","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(79)90597-X","article-title":"Fatal iatrogenic Cushing's syndrome","volume":"1","author":"Nathan","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.det.2015.05.004_bib24","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM199704103361516","article-title":"Adrenal insufficiency","volume":"336","author":"Bromberg","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2015.05.004_bib25","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0190-9622(08)82011-7","article-title":"Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids","volume":"29","author":"Walsh","year":"1993","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib26","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1365-2133.1998.02498.x","article-title":"Frequency of application of topical corticosteroids: an overview","volume":"139","author":"Lagos","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib27","series-title":"Comprehensive dermatologic drug therapy","first-page":"518","article-title":"Topical and intralesional chemotherapeutic agents","author":"Wolverton","year":"2013"},{"key":"10.1016\/j.det.2015.05.004_bib28","first-page":"126","article-title":"Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders","volume":"132","author":"Goodman","year":"1946","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.det.2015.05.004_bib29","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1396-0296.2003.01640.x","article-title":"Management with topical nitrogen mustard in mycosis fungoides","volume":"16","author":"Kim","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.det.2015.05.004_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/2013.jamadermatol.541","article-title":"Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial\u00a0testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides","volume":"149","author":"Lessin","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.det.2015.05.004_bib31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archderm.139.2.165","article-title":"Topical nitrogen mustard in the management of mycosis fungoides","volume":"139","author":"Kim","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib32","unstructured":"Federal Drug Administration. Valchlor (mechlorethamine) gel, for topical use. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/202317lbl.pdf. Accessed October 24, 2014."},{"key":"10.1016\/j.det.2015.05.004_bib33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/archderm.1982.01650150012011","article-title":"Treatment of mycosis fungoides total-skin electron-beam irradiation vs topical mechlorethamine therapy","volume":"118","author":"Hamminga","year":"1982","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib34","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0190-9622(88)70223-6","article-title":"Topical mechiorethamine therapy for early stage mycosis fungoides","volume":"19","author":"Ramsay","year":"1988","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib35","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0190-9622(89)70051-7","article-title":"Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma","volume":"20","author":"Vonderheid","year":"1989","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib36","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1468-3083.2011.04433.x","article-title":"Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis","volume":"27","author":"Lindahl","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2015.05.004_bib37","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.1987.5.11.1796","article-title":"Mycosis fungoides: management with topical nitrogen mustard","volume":"5","author":"Hoppe","year":"1987","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2015.05.004_bib38","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/1097-0142(19831215)52:12<2214::AID-CNCR2820521207>3.0.CO;2-H","article-title":"Ointment-based mechlorethamine treatment for mycosis fungoides","volume":"52","author":"Price","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.det.2015.05.004_bib39","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archdermatol.2011.98","article-title":"The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides","volume":"147","author":"Navi","year":"2001","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib40","doi-asserted-by":"crossref","unstructured":"Kim YH, Duvic M, Guitart J. Tolerability and efficacy of mechlorethamine 0.04% gel in CTCL (mycosis fungoides) after initial treatment with topical mechlorethamine 0.02% gel. The T-cell Lymphoma Forum. San Francisco, January 23-25, 2014.","DOI":"10.1200\/jco.2014.32.15_suppl.9093"},{"key":"10.1016\/j.det.2015.05.004_bib41","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/archderm.141.9.1117","article-title":"Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study","volume":"141","author":"de Quatrebarbes","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib42","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1001\/archderm.1975.01630160074008","article-title":"Mechlorethamine desensitization in therapy for mycosis fungoides","volume":"111","author":"Constantine","year":"1975","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib43","first-page":"39","article-title":"Contact urticaria and anaphylactic reactions induced by topical application of nitrogen mustard","volume":"68","author":"S\u00e1nchez Yus","year":"1977","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.det.2015.05.004_bib44","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1001\/archderm.1977.01640100065010","article-title":"Topical mechlorethamine. Cutaneous changes in patients with mycosis fungoides after its administration","volume":"113","author":"Price","year":"1977","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib45","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1001\/archderm.1977.01640040062009","article-title":"Topical chemotherapy and immunotherapy of mycosis fungoides: intermediate-term results","volume":"113","author":"Vonderheid","year":"1977","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib46","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S0190-9622(86)70128-X","article-title":"Cutaneous malignancies and metastatic squamous cell carcinoma following topical therapies for mycosis fungoides","volume":"14","author":"Abel","year":"1986","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib47","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0190-9622(82)70138-0","article-title":"Second cutaneous malignancies in patients with mycosis fungoides treated with topical nitrogen mustard","volume":"7","author":"Lee","year":"1982","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib48","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2133.1978.tb01962.x","article-title":"Mycosis fungoides, nitrogen mustard and skin cancer","volume":"99","author":"Du","year":"1978","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib49","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/bjd.12620","article-title":"Secondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: a 30-year population-based cohort study","volume":"170","author":"Lindahl","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib50","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0140-6736(68)91863-1","article-title":"Mustard gas as a cause of respiratory neoplasia in man","volume":"1","author":"Wada","year":"1968","journal-title":"Lancet"},{"key":"10.1016\/j.det.2015.05.004_bib51","first-page":"131","article-title":"On the late injuries following occupational inhalation of mustard gas, with special references to carcinoma of the respiratory tract","volume":"13","author":"Yamada","year":"1963","journal-title":"Acta Pathol Jpn"},{"key":"10.1016\/j.det.2015.05.004_bib52","unstructured":"Valchlor [package insert]. San Francisco, CA: Actelion Pharmaceuticals, inc; 2013."},{"key":"10.1016\/j.det.2015.05.004_bib53","first-page":"100","article-title":"The influence of the N-mustard derivative \u201ccytostasan\u201d on pregnancy and fetal development in the rat","volume":"139","author":"Wendler","year":"1976","journal-title":"Anat Anzr"},{"key":"10.1016\/j.det.2015.05.004_bib54","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/blood.V8.6.576.576","article-title":"The use of nitrogen mustard in the management of two pregnant lymphoma patients","volume":"8","author":"Deuschle","year":"1953","journal-title":"Blood"},{"key":"10.1016\/j.det.2015.05.004_bib55","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/archderm.1972.01620110013003","article-title":"Treatment of mycosis fungoides with topical nitrosourea compounds","volume":"106","author":"Zackheim","year":"1972","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib56","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/0190-9622(90)70112-U","article-title":"Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients","volume":"22","author":"Zackheim","year":"1990","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib57","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1396-0296.2003.01641.x","article-title":"Topical carmustine (BCNU) in the treatment of mycosis fungoides","volume":"16","author":"Zackheim","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.det.2015.05.004_bib58","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2133.1977.tb15429.x","article-title":"Percutaneous absorption of 1,3-bis (2-chlorethyl)-1-nitrosourea (BCNU, carmustine) in mycosis fungoides","volume":"97","author":"Zackheim","year":"1977","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib59","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0889-8588(18)30057-1","article-title":"Topical treatment of early cutaneous T-cell lymphoma","volume":"9","author":"Ramsay","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.det.2015.05.004_bib60","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/archderm.1985.01660110058016","article-title":"Topical carmustine therapy for lymphomatoid papulosis","volume":"121","author":"Zackheim","year":"1985","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib61","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/archderm.1966.01600270015003","article-title":"Pigmentation due to a new antitumor agent: effects of topical application of BCNU [1,3-Bis(2-Chloretyhl)-1-Nitrosourea]","volume":"94","author":"Frost","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib62","first-page":"655","article-title":"Skin directed therapy for mycosis fungoides: a review","volume":"7","author":"Berthelot","year":"2008","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib63","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/carcin\/8.9.1219","article-title":"Inhibition of O6-alkylguanine-DNA-alkyltransferase activity potentiates cytotoxicity and induction of SCEs in human glioma cells resistant to 1,3-bis(2-chloroethyl)-1-nitrosourea","volume":"8","author":"Aida","year":"1987","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.det.2015.05.004_bib64","series-title":"The retinoids","first-page":"210","article-title":"Cellular biology and biochemistry of retinoids","author":"Gudas","year":"1994"},{"key":"10.1016\/j.det.2015.05.004_bib65","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/archdermatol.2011.2797","article-title":"Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type","volume":"148","author":"Apisarnthanarax","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib66","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0190-9622(83)70143-X","article-title":"Topical carmustine (BCNU) for mycosis fungoides and related disorders: a 10-year experience","volume":"9","author":"Zackheim","year":"1983","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib67","series-title":"Comprehensive dermatologic drug therapy","article-title":"Topical retinoids in comprehensive dermatologic drug therapy","author":"Wolverton","year":"2013"},{"key":"10.1016\/j.det.2015.05.004_bib68","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1096\/fasebj.10.9.8801176","article-title":"A\u00a0decade of molecular biology of retinoic acid receptors","volume":"10","author":"Chambon","year":"1996","journal-title":"FASEB J"},{"key":"10.1016\/j.det.2015.05.004_bib69","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1396-0296.2003.01644.x","article-title":"Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma","volume":"16","author":"Zhang","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.det.2015.05.004_bib70","article-title":"Role of retinoids in differentiation and carcinogenesis","volume":"73","author":"Sporn","year":"1984","journal-title":"J\u00a0Natl Cancer"},{"key":"10.1016\/j.det.2015.05.004_bib71","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/jnci\/84.4.241","article-title":"13-cis-retinoic acid plus interferon-2a: highly active systemic therapy for squamous cell carcinoma of the cervix","volume":"84","author":"Lippman","year":"1992","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.det.2015.05.004_bib72","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1021\/jm00016a018","article-title":"Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells","volume":"38","author":"Boehm","year":"1995","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.det.2015.05.004_bib73","first-page":"1234","article-title":"Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action","volume":"8","author":"Zhang","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.det.2015.05.004_bib74","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","article-title":"Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial","volume":"49","author":"Heald","year":"2003","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib75","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1001\/archderm.138.3.325","article-title":"Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma","volume":"138","author":"Breneman","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib76","first-page":"514","article-title":"Bexarotene ligand pharmaceuticals","volume":"1","author":"Hurst","year":"2000","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.det.2015.05.004_bib77","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1001\/archderm.138.3.398","article-title":"Bexarotene gel: a Food and Drug Administration-approved skin-directed therapy for early-stage cutaneous T-cell lymphoma","volume":"138","author":"Liu","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib78","unstructured":"Targretin\u00ae (bexarotene) gel 1% [package insert]. Available at: http:\/\/www.drugbank.ca\/system\/fda_labels\/DB00307.pdf?1265922814. Accessed October 27, 2014."},{"key":"10.1016\/j.det.2015.05.004_bib79","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000068451","article-title":"Bexarotene is a new treatment option for lymphomatoid papulosis","volume":"206","author":"Krathen","year":"2003","journal-title":"Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib80","first-page":"169","article-title":"Folliculotropic mycosis fungoides responding to bexarotene gel","volume":"7","author":"Walling","year":"2008","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib81","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaad.2003.09.005","article-title":"Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study","volume":"50","author":"Apisarnthanarax","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.det.2015.05.004_bib82","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1001\/archderm.136.12.1461","article-title":"Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome\u2013related Kaposi sarcoma using alitretinoin gel","volume":"136","author":"Duvic","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib83","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2165\/00128071-200102020-00004","article-title":"Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma","volume":"2","author":"Bodsworth","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib84","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1046\/j.1365-4362.2002.01363.x","article-title":"Treatment of cutaneous T-cell lymphoma with alitretinoin gel","volume":"41","author":"Bassiri-Tehrani","year":"2002","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib85","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0190-9622(97)80398-2","article-title":"Tazarotene gel: efficacy and safety in plaque psoriasis","volume":"37","author":"Weinstein","year":"1997","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib86","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/archderm.139.5.624","article-title":"Phase 1\/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides","volume":"139","author":"Demierre","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib87","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s102270000032","article-title":"Management of psoriasis vulgaris with methotrexate 0.25% in a hydrophilic gel: a placebo-controlled, double-blind study","volume":"5","author":"Syed","year":"2001","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.det.2015.05.004_bib88","first-page":"906","article-title":"Successful treatment of patch type mycosis fungoides with tacrolimus ointment 0.1%","volume":"5","author":"Rallis","year":"2006","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib89","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/archdermatol.2010.60","article-title":"Posttransplant cutaneous T-cell lymphoma: case reports and review of the association of calcineurin inhibitor use with posttransplant lymphoproliferative disease risk","volume":"146","author":"Pomerantz","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib90","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jaad.2004.04.049","article-title":"Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream","volume":"52","author":"Deeths","year":"2005","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib91","first-page":"148","article-title":"Imiquimod in mycosis fungoides","volume":"18","author":"Mart\u00ednez-Gonz\u00e1lez","year":"2008","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib92","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archderm.138.9.1137","article-title":"Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod","volume":"138","author":"Suchin","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib93","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000070962","article-title":"Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoides","volume":"207","author":"Dummer","year":"2003","journal-title":"Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib94","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1365-2230.2006.02208.x","article-title":"Treatment of mycosis fungoides with imiquimod 5% cream","volume":"31","author":"Ariffin","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib95","first-page":"167","article-title":"Efficacy of imiquimod in solitary plaques of mycosis fungoides","volume":"27","author":"Onsun","year":"2005","journal-title":"Int J Tissue React"},{"key":"10.1016\/j.det.2015.05.004_bib96","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4321\/S0365-66912006000400009","article-title":"Imiquimod in treatment of palpebral mycosis fungoides","volume":"81","author":"Soler-Machin","year":"2006","journal-title":"Arch Soc Esp Oftalmol"},{"key":"10.1016\/j.det.2015.05.004_bib97","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-2133.2006.07599.x","article-title":"Solitary plaque mycosis fungoides of the penis responding to topical imiquimod therapy","volume":"156","author":"Chiam","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib98","first-page":"446","article-title":"Unilesional mycosis fungoides successfully treated with topical imiquimod","volume":"16","author":"Ardig\u00f2","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.det.2015.05.004_bib99","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S1068-607X(98)00034-1","article-title":"Percutaneous penetration of Aldara cream, 5% during the topical treatment of genital and perianal warts","volume":"5","author":"Owens","year":"1998","journal-title":"Prim Care Update Ob Gyns"},{"issue":"11","key":"10.1016\/j.det.2015.05.004_bib100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamadermatol.2014.929","article-title":"Histologic features mimicking mycosis fungoides induced by imiquimod, 5%: a potential pitfall for dermatopathologists","volume":"150","author":"Altamura","year":"2014","journal-title":"JAMA Dermatol"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515000492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863515000492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T01:38:04Z","timestamp":1599442684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863515000492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0733863515000492"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2015.05.004","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Skin-Directed Therapies in Cutaneous T-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2015.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}